Ranbaxy Laboratories, Inc.

Ranbaxy Laboratory Limited

Anita Chugh

Yatendra Kumar

Mohammad Salman

Ram Chander Aryan

Naresh Kumar

Anita Mehta

Pakala Kumara Savithru Sarma

Sankaranarayanan Dharmarajan

Kumar Hari Bhushan

Radhakrishnan Gowri Shankar

Neelima Sinha

Sanjay Kumar Jain

Jang Bahadur Gupta

Nitya Anand

Jitendra Anant Sattigeri

Kirandeep Kaur

Laxminarayan G Hegde

Arundutt Vishwanatham Silamkoti

Shankar Jayram Shetty

Vikram Krishna Ramanathan

Vikram Krishna Ramanthan

Jitendra Sattiegeri

The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Substituted pyrrole derivatives and their use as HMG-CO inhibitors

This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0] hexanes, and 2,4,6-trisubstituted derivatives. The invention also relates to pharmaceutical compositions containing the compounds and the methods of treating the diseases mediated through muscarinic receptors.

Azabicyclo derivatives as muscarinic receptor antagonists

This invention generally relates to muscarinic receptor antagonists of formula (I) which are useful, among other uses for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

The optically active compound, R (&#x2212;)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide in good optical purity, a metabolite of the &#x3b1;-adrenergic blocking agent tamsulosin, and methods for the preparation thereof. Pharmaceutical compositions including the optically active compound and methods of treatment comprising administration of an effective &#x3b1;-adrenergic antagonistic amount of such compositions to mammals.

Tamsulosin derivative

The present invention relates to a novel 1,4-disubstituted piperazine derivatives of Formula I,and their pharmaceutically acceptable acid addition salts having excellent uro-selective &#x3b1;-adrenoceptor antagonistic activity exceeding those of previously described compounds. The compounds of the present invention hold promise for treating the symptoms of benign prostatic hyperplasia (BPH). The invention also relates to methods for making the novel compounds, pharmaceutical compositions containing the compounds, and method of treating the symptoms of benign prostatic hyperplasia using the compounds.

1,4-Disubstituted piperazine derivatives useful as uro-selective &#x3b1;1-adrenoceptor blockers

The optically active compound, R(&#x2212;)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide in good optical purity, a metabolite of the &#x3b1;-adrenergic blocking agent tamsulosin, and methods for the preparation thereof. Pharmaceutical compositions including the optically active compound and methods of treatment comprising administration of an effective &#x3b1;-adrenergic antagonistic amount of such compositions to mammals.

Growing community of inventors

Delhi, India

Anita Chugh